GSK PLC Sponsored ADR (GSK) To Go Ex-Dividend on November 13th

GSK PLC Sponsored ADR (NYSE:GSK) announced a quarterly dividend on Wednesday, October 28th. Shareholders of record on Friday, November 13th will be paid a dividend of $0.4518 per share by the pharmaceutical company on Thursday, January 7th. This represents a $1.81 annualized dividend and a yield of 3.5%. The ex-dividend date is Friday, November 13th. This is a 0.1% increase from GSK’s previous quarterly dividend of $0.4515.

GSK has decreased its dividend by an average of 0.1% per year over the last three years. GSK has a payout ratio of 36.6% indicating that its dividend is sufficiently covered by earnings. Research analysts expect GSK to earn $4.99 per share next year, which means the company should continue to be able to cover its $1.77 annual dividend with an expected future payout ratio of 35.5%.

GSK Price Performance

GSK opened at $51.27 on Wednesday. The stock’s 50 day simple moving average is $49.30 and its 200 day simple moving average is $52.39. GSK has a 1 year low of $45.81 and a 1 year high of $61.69. The firm has a market cap of $103.70 billion, a price-to-earnings ratio of 17.81, a PEG ratio of 2.32 and a beta of 0.28. The company has a debt-to-equity ratio of 1.18, a current ratio of 0.86 and a quick ratio of 0.56.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on GSK shares. Deutsche Bank Aktiengesellschaft reaffirmed a “neutral” rating on shares of GSK in a research report on Tuesday, September 29th. Morgan Stanley reiterated an “underweight” rating on shares of GSK in a report on Tuesday, August 25th. Berenberg Bank reiterated a “buy” rating on shares of GSK in a research note on Tuesday, October 6th. Wolfe Research initiated coverage on shares of GSK in a research report on Friday, October 9th. They set an “outperform” rating and a $70.00 price objective for the company. Finally, JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of GSK in a report on Thursday, October 1st. Three equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $56.30.

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.